Get started

Biotech

Bluebird Bio (NASDAQ: BLUE) Posing Strong Bearish TrendBLUE is currently trading above its 50-day and 200-day simple moving averages (SMA), indicating a bullish trend. However, the 50-day SMA is below the 200-day SMA, forming a death cross pattern, which is a bearish signal. The 20-day exponential moving average (EMA) is also above the current price, acting as a resistance level. A break above the 20-day EMA could signal a continuation of the uptrend, while a break below the 50-day SMA could signal a reversal of the trend. Earnings and Revenue: The earnings per share (EPS) of BLUE is expected to decline by 37.50% in the current quarter (Dec 2023) and increase by 333.30% in the next quarter (Mar 2024). The EPS for the current year (2023) is estimated to be -$11.7, which is a 59.10% decrease from the previous year (2022). The EPS for the next year (2024) is projected to be -$8.6, which is an 26.50% increase from the current year2. The revenue of BLUE is expected to decrease by 3.10% in the current quarter (Dec 2023) and increase by 9.00% in the next quarter (Mar 2024). The revenue for the current year (2023) is estimated to be $289.2 million, which is a 0.80% decrease from the previous year (2022). The revenue for the next year (2024) is forecasted to be $313.6 million, which is a 8.40% increase from the current year. The technical analysis of BLUE shows that the stock is in a mixed trend, with some bullish and bearish signals. The stock is also facing low volatility and uncertain momentum. The earnings and revenue estimates suggest that the company is going through a challenging period, but might recover in the future.
NASDAQ:BLUEShort
by DEXWireNews
SRPT Sarepta Therapeutics Potential Buyout SoonIf you haven`t bought SRPT here: Then you need to know that there is a Massive catalyst coming! Sarepta Therapeutics is going to announce Duchenne muscular dystrophy Phase 3 data for its SRP-9001-301 - (EMBARK) by mid November. This week institutions bought calls worth more than $10Mil that SRPT Sarepta Therapeutics will trade above $135 by November 17. Some even bought the $210 strike price! They also have a big partnership with the giant Roche Holding AG (RHHBY). I think SRPT Sarepta Therapeutics is well positioned for a potential takeover soon! Looking forward to read your opinion about it.
NASDAQ:SRPTLong
by TopgOptions
NVTA Invitae Corporation All Time Low | Potential Buyout !Last year in Autumn we had this buyout rumor. I remember back then Exact Sciences said to approach Invitae about a potential merger. Now, NVTA, Invitae Corporation, is trading at an all-time low, $0.62. Some deals take one or two years to perfect, and we don't know what caused the recent price decrease. Sometimes this happens before an announcement. Today, Invitae announced the appointment of finance veteran Ana Schrank as CFO; she spent more than 20 years at McKesson Corporation where she held leadership roles. Could this CFO be hired ahead of a takeover?! We don't know! But with an RSI of 19.34 and an all-time low, along with ARK Invest being the 2nd largest shareholder at an average price of $15.08, I think this looks like a great buying opportunity! Looking forward to read your opinion about it!
NLong
by TopgOptions
2
GRI Bio periodic pumps GRI Bio recently underwent a 1/30 split on April 24th, accompanied by a merger/restructure of Vallon Pharmaceuticals. The stock price immediately tanked approx. 50% in the following days. The price has held above the low of $5.50 on April 26th for over a month. Based on past performance, this stock has a tendency to jump 30 to >200% in a single day. GRI Bio has touted the merger and restructuring will bring "near term" value to stock holders, and perhaps a catalyst will emerge in the coming month(s). I think this is a safe long with stops at $5.50 or thereabouts. A jump to $10 or higher seems reasonable, but will likely retrace immediately.
NASDAQ:GRILong
by nothximgood
1
ETON Biotech Big Earning Beat Pullback LONGETON jumped on a big earnings report a week ago. This small cap biotechology company is making big money and traders responded. It has now experienced a standard 0.5 Fib level retracement pullback and traders early in the jump take profit. At this level new buyers have equilibrated with those selling their shares and taking profit. The ZL MACD lines are ready to cross bearly under the histogram whose negative/ red amplitude is reverting toward the zero line. The lines of the dual time frame RS indicator have held above the 50 level. In consideration of this healthy pullback and buying /selling pressure equilibrium I will take a long trade looking for 15-20% upside considering also the uprising fundamentals of the stock based on the big earnings beat.
NASDAQ:ETONLong
by AwesomeAvani
8
NKTR High Tight Flag- Pre-Earnings High Flyer LONGNKTR is due for earnings on August 8th. The price from the opening bell on the 7th pump nearly 100% to over $1.00 and then faded by a couple of cents. The Price Momentum Oscillator and ZL MACD indicators tracked the high velocity action into a high tight type bull falg which is often considered to be predictive of another leg up of similar magnitude. I will be watching this in the premarket upcoming and also at the report of earnings. I hope to catch a decent ride. If I do get it I will quit the ride as soon as the indicators flip signals. This could be a good one. Buyer anticipation and sentiment could yield great profit in little time the money is exposed to the market.
NASDAQ:NKTRLong
by AwesomeAvani
3
QSI Quantum-Si Earnings Release on Monday, Before the BellIf you haven`t bought the Double Bottom: Then you should know that QSI, Quantum-Si incorporated, also known as The Protein Sequencing Company is bringing single-molecule protein sequencing to every lab, everywhere, enabling new discoveries that will transform the world we live in. Importance of Protein Sequencing: - Understanding Cellular Processes: Proteins are involved in virtually every cellular process, and their sequencing is vital for understanding how these processes are regulated and how dysfunction leads to diseases. - Drug Development: Protein sequencing assists in drug discovery by identifying specific targets for pharmaceutical intervention. This knowledge enables the design of drugs that can interact with specific proteins, thereby treating diseases more effectively. - Bioengineering and Enzyme Production: Protein sequencing is critical in the field of bioengineering, allowing the design of proteins with tailored functions for various applications, including industrial enzyme production and bioremediation. I think protein sequencing should have the same importance as gene sequencing. Gene sequencing has revolutionized medical research, agriculture, and our comprehension of evolutionary history. On the other hand, protein sequencing has paved the way for targeted drug development, bioengineering, and the investigation of cellular processes. QSI has cash and cash equivalents of $322.1 million as of March 31,2023 to provide a runway to support operations and invest in the business into 2026, and NO debt! This Quarter started he sale of PlatinumTM instruments and kits with a gross margin of 48.8%. QSI has a Market Cap of $485Mil vs CRSP, my favorite gene editing company, with a Market Cap of 4.046Bil. So there is still a lot of upside in QSI Quantum-Si incorporated! Looking forward to read your opinion about it.
NASDAQ:QSILong
by TopgOptions
ZYXI reverses from whipsaw volatility LONGXYNI is now ready to reverse long. I analyze this because ZYXI has dropped from overvalued and overbought through the fair value zone into undervalued territory in three trading days by viewing the anchored VWAP bands and the volume profile, The mean VWAP and POC line are confluent at 7.25. This is the logical first target. The MACD lines are negative 4X the amplitude of the the negative histogram on the 2H and impending cross. The mass index is a sensitive signal of reversal potential is about to trigger and probably has done so on lower time frames. I will take ZYXI long with a good entry to be found on a 15-30 minute the time frame when I get an alert that it has crossed over the hand-drawn resistance trend line. I am expecting 8% before the first take profit target and 12% on the overall trade over the next 5 trading days or so. A modest profit for low risk, I think. Anyone in faraway places from the Wall Street market manipulators and FDA, this one is for you.
NASDAQ:ZYXILong
by AwesomeAvani
4
CRSP: Big orrection after the next rally, but buy-the-dip.I believe that CRSP (Crispr Therapeutics) is about to undergo a severe correction soon. I scaled into this stock during the latter part of 2022 and the first part of 2023 and it is up nearly 70% and has generated about 40% of pure alpha for me relative to the SPX. So this has been an amazing performer for my total portfolio. I believe this run may be nearing a pullback and I expect the correction to be a very severe one. My suggestion is that this will form a triple-bottom/inverse head-and-shoulders pattern because this will be a subwave 2 correction and in theory, it should not overthrow the recent low by very much. I think the post-correction rally will be sizeable (it'll be a macro Wave 3) and the catalyst for this rally will be the steady trend of slowly improving earnings that they have demonstrated over the past year. (3 successive quarters of positive earnings calls - this has not been achieved since 2017) So, in essence, presuming nothing else changes, I believe we should buy the next dip for a significant Wave 3 rally that will exceed the all-time highs. In the meantime, expect lots of volatility, if you don't have the stomach for taking drawdowns or losses in the interim, you may want to sell the next rally so that you can buy back in. I will probably pursue this course of action myself purely as a matter of greed to preserve the alpha I have managed to capture. Happy biotech trading!
NASDAQ:CRSPLong
by RogueEconomics
FLMD biotechology rising post earningsFLMD had earnings in May with positive earnings beating the expectation of analysts that it would continue to lose quarter after quarter. Investors and traders have reacted with a 80% run-up in the month after those earnings. On the 30-minute chart besides the consistent uptrend with minor corrections, what stands out for me is the increasing volumes relative to volumes before the last earnings report. Off the chart, I find information that insider trading with buying more shares on top of existing holdings leads me to believe that this company expects increasing revenues and sustained earnings.
NASDAQ:LFMDLong
by AwesomeAvani
AUTL Is this a pump and dump?AUTL on the one-hour chart had a spontaneous parabolic move without a catalyst as best as I can tell. Earnings ten days ago were decent but nothing special. AUTL as a biotech firm is losing cash just not as much as analysts predicted. In the parabolic move very few shares were traded between $2.00 and $2.40 as per the volume profile Overall a massive volume occurred compared with the entire year although there was a bit in the runup to earnings. I suspect a pump and dump and think it might be worth playing. Insiders could be manipulating the shares and acting as a team. The zero-lag MACD suggests that the top has been reached. I believe that insiders will be selling quickly and short sellers will be joining in. I will be one of the latter. Retail buyers could be stuck bag holding if caught by surprise. Once price drops to $4.00 the bearish momentum will kick in due to the volume void on the profile. Accordingly, I will buy a group of call options when AUTL hits $4.05 set a stop loss and await the flush back down to $2.00. If things go well this will be over a 100% return on investment and 300% return on risk in one day. The contracts for 6/16 ( $5.00) are about $250 with about 25% spread between the bid and ask.
NASDAQ:AUTLShort
by AwesomeAvani
Pullback Buy in TGTXBiotech stocks can make huge moves, and this one is no exception. TGTX more than doubled in a month and is showing no signs of slowing down. Slower-trending, blue chip stocks tend to ride their 50-day moving average (red line on chart) on the way up. Stronger stocks tend to hold their 21-day moving average (blue line). But with high-flying honey badger stocks like TGTX, you are lucky to get a pullback to the 10-day (yellow line). TGTX touched its 10-day exponential moving average on Friday, making this the first real pullback buying opportunity since the initial surge. I would consider buying here with an 8-10% stop loss.
NASDAQ:TGTXLong
by rossgivens
VYNE Biotech Post Earnings VYNE had a favorable earnings report last week. Fundamentally, analysts predict ( linked) approximately a doubling of the shart price in the next year. Like many low share priced biotechnology stocks the price is based on perceived future earnings which can be affected by favorable FDA process, or well-received research at industry conferences and changing financials within the company. In general, they have a low beta meaning these stocks are not general market responsive and run on their own present or future merits. On the 15-minute chart VYNE was trending down into earnings and the pivoted with a reversal into the present. The Luxalgo AI "Echo indicator" predicts an upside of 20% in the next two days before a consolidation period. The "Trendflex" indicator has flipped to postiive and green. I will take this long trade with a stop loss of $0.15 per share and target of $9.00 over two days for a 20% ROI and a R:R of 0.15 risk / $ 1.50 reward for a 10:1> Iwill only take biotechology trades long with a high R:R due to the inheret risk level.
NASDAQ:VYNE
by AwesomeAvani
BLUE Biotechnology New Earnings Catalyst LONGBlueBird Bio / BLUE had an earnigns report this past week showing earnings for the firat time but revenue was far below analyst's projections. Price has appreciated 40% in the 4 weeks since earnings which is about 500% annualized. GO BLUE. On the daily chart, price was above VWAP and consolidating much of last fall then dropped this YTD until the earnings report of last week. An uptrend is seen after the earnings. This has been a significant reversal sustained over the past month with price rising above the support / demand zone below it. At present, price is one standard deviation below VWAP making it undervalued and ascending. I see this as a risky long trade like many biotechology penny stocks but with a decent probability of profit in consideration of a target of 6.15 which is the top of the long term high volume area. the stop loss is just below the POC line of the volume profile at 3.15 An entry at 4.62 ( limit order above SMA200 (redlne) would yield at profit of 1.50 with a risk of 0.48 making for a R:R of 3:1. Another earnings report is coming up this week. If it is favorable, BLUE could go parabolic to hit the target in a day or two. If not, it will be time to exit the trade.
NASDAQ:BLUELong
by AwesomeAvani
7
Cathie Wood is long BEAM, But I will be Strong Short #CathieWood Baught this stock...I analyzed it....and …...well....I would do exact the opposite...... But why? Technical Analysis Let forget eveything you know about technical analysis, and let together tell this story....logically.. At 76-71 USD AGGRESSIVE SELLERS FORCED THE PICE DOWN 29,72 USD BUYERS DEFENDED THIS Area(ZONE) as well the sellers took partial profits, and accumulated their positions ,but this time more powerfully and aggressive at 64-61USD zone THE PRICE MOVED DOWN, Institutional buyers took patial profits,(the best decision they could do OTHERWISE THEY WOULD LOSE ALL THIER PROFITS LOOK AT THE PICE OF TODAY The retail traders who followed the news and the hype baught Beam hoping that the share prce will fly to the moon,but...... At 64-61 who is waiting there? YES THE AGGRESSIVE SELLERS!!!! NOW THEY FORCED MUCH MORE ORDERS TO SEND THE PRICE To the....where we are now.... Bad for the buyers...Some buyers took profits, some took losses, and to compensate thier losses, they started to sell short the market.... At 28,80(YELLOW LINE) we are now at the weak support(low volume) The market could make a retracement to 44,94USD where the sellers and BEARS are waiting of them.....to do what? Well you know it..... Otherwise...more selles (former retail trades bulls) could decide to sell the maket from here.... WE HAVE A LONG DISTANCE TO GO DEEPER.... Targets short 13,75 8,68 3,82 1,25 . . Wood's flagship ARK Innovation ETF has loaded up in recent weeks on Beam Therapeutics (BEAM 1.11%). The gene-editing stock currently ranks as the ETF's 18th-largest holding. It's also the ninth-largest position in Wood's ARK Genomic Revolution ETF. Beam Therapeutics is a pioneer in base editing. Most types of gene editing involve double-strand breaks in DNA that can cause random unwanted insertions and deletions. Base editing is highly precise, with no double-strand breaks and no off-target genetic changes. Because of these characteristics, base editing holds tremendous promise as a method for developing therapies targeting genetic diseases and "off the shelf" cell therapies for treating cancer. So far, Beam has advanced two base-editing candidates into clinical testing. It's evaluating BEAM-101 as a treatment for two rare blood disorders: sickle cell disease and beta-thalassemia. And the company expects to begin dosing patients in a phase 1 study of experimental cancer cell therapy BEAM-201 by mid-2023. Those two programs could be joined by two others soon. Beam hopes to submit for regulatory approvals to start clinical studies of BEAM-301 as a treatment for glycogen storage disease type 1a and BEAM-302 as a treatment for severe alpha-1 antitrypsin deficiency by early 2024. The company has a long way to go. But if its base-editing programs prove to be safe and effective, Beam could be a massive winner.
CAPITALCOM:BEAMShort
by DaveBrascoFX
1
MRNA ? Buy Weakness MRNA descended this past winter off a head-and-shoulders pattern on the daily chart just under the demand zone as shown by the LuxAlgo indicator. Price is now in a downtrend heading into earnings tomorrow. MRNA needs to show something good otherwise it will break through the demand zone and keep going down. This is a risky earnings play betting that something will show up on the report to buoy up the company and its stock. I will risk 0.01% of the trading account on a call option with DTE 5/19/23 looking for a minor surge and so a good quick profit. ( see also the link below)
NASDAQ:MRNALong
by AwesomeAvani
LABU Triple Leveraged Biotech Sector ETFOn the 4H Chart LABU is trending up since March 27th. Last week there was a small pullback which was met with more buying activity. On the volume indicator, the volume now is approximately 10X day by day compared with March's averages. It is this buying that is driving the bullish momentum. Small-cap speculative biotech companies are in a growth mode right now no matter adverse economic conditions for those yet to have any earnings. Big pharma is more concerned about federal attempts to further regulate prices than the economy. On the volume profile, price has ascended to above the high volume trading area on the strength of buyer interest propelling the momentum. Overall, this looks to be a decent long trade. The target is $ 9.00 the YTD high back in February.
AMEX:LABULong
by AwesomeAvani